Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 3

1(25.0%)

N/A

1(25.0%)

4Total

Phase 2(2)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT03058224Not ApplicableCompleted

Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia

Role: collaborator

NCT01757613Phase 2Completed

Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis

Role: collaborator

NCT00656422Phase 3Terminated

Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine

Role: collaborator

NCT00518024Phase 2Completed

Safety and Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus

Role: collaborator

All 4 trials loaded